Shots:
- The US FDA has approved Pixclara (floretyrosine F 18) for pts (≥1mos.) as the FET-PET imaging drug for glioma, enabling PET imaging to help differentiate recurrent or progressive glioma from treatment-related changes
- Pixclara comprises a small-molecule targeting agent & fluorine-18; it binds with LAT1 & LAT2 transporters after IV administration, allowing the radioisotope’s emissions to be detected by PET imaging
- The approval expands Telix’s Precision Medicine & theranostics portfolio, while Pixclara (TLX101-Px) is being evaluated in a P-III study for potential expansion into brain metastases diagnosis
Ref: Globenewswire | Image: Telix | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
